World News
native adds ad now
loading...
Wednesday, 30 May 2018
FDA expedites review of Novartis drug Promacta® for first-line severe aplastic anemia (SAA)
FDA expedites review of Novartis drug Promacta® for first-line severe aplastic anemia (SAA)
P&T Community
Novartis anemia drug gets FDA priority review
MarketWatch
Full coverage
from Health - Google News https://ift.tt/2J0Fqe4
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment